John Kurhanewicz (PhD) has been UCSF faculty in the Departments of Radiology and Biomedical Imaging, and Pharmaceutical Chemistry since 1993, and he joined the UCSF Department of Urology with a joint appointment in 2007. He is a member of the California Institute for Quantitative Biology, the UCSF Helen Diller Family Comprehensive Cancer Center, and the UCSF-UC Berkeley Bioengineering Graduate Group. He serves on grant review panels for the National Cancer Institutes, the National Institute of Health, the American Cancer Society, and the Department of Defense. He has served as a scientific reviewer for over 20 different journals and has been a major contributor, with his courses in molecular and advanced imaging in oncology, to meetings of the International Society of Magnetic Resonance in Medicine and Radiologic Society of North America. He is recognized internationally for his research in the magnetic resonance imaging (MRI) and spectroscopic imaging (MRSI) of patients with prostate cancer and was involved in the development and translation of this technology into the clinic. He is the Director of the UCSF Prostate Imaging Program and the Hyperpolarized High-Field NMR Facility For Metabolic Profiling of Human Disease. He has been awarded major grants for the development and application of MR metabolic imaging to prostate cancer patients and biomarker development.
John Kurhanewicz (PhD) has been UCSF faculty in the Departments of Radiology and Biomedical Imaging, and Pharmaceutical Chemistry since 1993, and he joined the UCSF Department of Urology with a joint appointment in 2007. He is a member of the California Institute for Quantitative Biology, the UCSF Helen Diller Family Comprehensive Cancer Center, and the UCSF-UC Berkeley Bioengineering Graduate Group. He serves on grant review panels for the National Cancer Institutes, the National Institute of Health, the American Cancer Society, and the Department of Defense. He has served as a scientific reviewer for over 20 different journals and has been a major contributor, with his courses in molecular and advanced imaging in oncology, to meetings of the International Society of Magnetic Resonance in Medicine and Radiologic Society of North America. He is recognized internationally for his research in the magnetic resonance imaging (MRI) and spectroscopic imaging (MRSI) of patients with prostate cancer and was involved in the development and translation of this technology into the clinic. He is the Director of the UCSF Prostate Imaging Program and the Hyperpolarized High-Field NMR Facility For Metabolic Profiling of Human Disease. He has been awarded major grants for the development and application of MR metabolic imaging to prostate cancer patients and biomarker development.